scholarly journals Human HER2 overexpressing mouse breast cancer cell lines derived from MMTV.f.HuHER2 mice: characterization and use in a model of metastatic breast cancer

Oncotarget ◽  
2017 ◽  
Vol 8 (40) ◽  
pp. 68071-68082 ◽  
Author(s):  
Sunju Park ◽  
Jessie R. Nedrow ◽  
Anders Josefsson ◽  
George Sgouros
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Metastatic Breast ◽  
Cancer Cell Lines ◽  
Breast Cancer Cell Lines ◽  
Mouse Breast Cancer

Chondroitin sulfate glycosaminoglycans as major P-selectin ligands on metastatic breast cancer cell lines

2007 ◽  
Vol 120 (6) ◽  
pp. 1179-1191 ◽  
Author(s):  
Behjatolah Monzavi-Karbassi ◽  
J. Steven Stanley ◽  
Leah Hennings ◽  
Fariba Jousheghany ◽  
Cecile Artaud ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Chondroitin Sulfate ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Metastatic Breast ◽  
Breast Cancer Cell Lines ◽  
Metastatic Breast Cancer Cell ◽  
Selectin Ligands

scholarly journals Organ-specific isogenic metastatic breast cancer cell lines exhibit distinct Raman spectral signatures and metabolomes

Oncotarget ◽  
2017 ◽  
Vol 8 (12) ◽  
pp. 20266-20287 ◽  
Author(s):  
Paul T. Winnard ◽  
Chi Zhang ◽  
Farhad Vesuna ◽  
Jeon Woong Kang ◽  
Jonah Garry ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Metastatic Breast ◽  
Breast Cancer Cell Lines ◽  
Spectral Signatures ◽  
Organ Specific ◽  
Raman Spectral

scholarly journals c-myc regulates the sensitivity of breast cancer cells to palbociclib via c-myc/miR-29b-3p/CDK6 axis

2020 ◽  
Vol 11 (9) ◽  
Author(s):  
Wenfei Ji ◽  
Wenwen Zhang ◽  
Xin Wang ◽  
Yaqin Shi ◽  
Fang Yang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Xenograft Model ◽  
Metastatic Breast ◽  
Cancer Cell Lines ◽  
The Cancer Genome Atlas ◽  
Tumor Xenograft ◽  
Breast Cancer Cell Lines

Abstract Palbociclib, a CDK4/6 inhibitor, has been granted accelerated approval by US FDA for hormone receptor-positive HER2-negative metastatic breast cancer. To determine potential biomarkers of palbociclib sensitivity to assist in patient selection and clinical development, we investigated the effects of palbociclib in a panel of molecularly characterized breast cancer cell lines. We quantified palbociclib sensitivity and c-myc expression in 11 breast cancer cell lines, 124 breast cancer samples, and The Cancer Genome Atlas database. We found non-TNBC subtypes were more sensitive to palbociclib than TNBC. Activation of c-myc led to differential palbociclib sensitivities, and further inhibition of c-myc enhanced palbociclib sensitivity. Moreover, we identified for the first time a c-myc/miR-29b-3p/CDK6 axis in breast cancer that could be responsible for c-myc-induced palbociclib insensitivity, in which c-myc activation resulted in downregulation of miR-29b-3p, further activated CDK6 and inhibited cell-cycle arrest at G1 phase. Moreover, downregulated (inactived) c-myc-induced oncogenic addiction could increase palbociclib efficacy, using both Xenograft model and patient-derived tumor xenograft (PDTX) model. Our finding extends the concept of combined blockade of the CDK4/6 and c-myc signaling pathways to increase palbociclib sensitivity, making c-myc a promising biomarker for palbociclib sensitivity in breast cancer.

Sign in / Sign up

Export Citation Format

Share Document